Abstract
Hypertrophic cardiomyopathy (HCM) is microscopically characterized by cardiomyocyte hypertrophy, myofibrillar disarray, and fibrosis. During the evolvement of the hypertrophic disease, myocardium suffers a heterogeneous remodeling which includes enhancement of extracellular matrix. The most commonly used pharmacological agents are β- blockers and verapamil, a calcium antagonist, which are the mainstay of therapy. Their proposed mechanisms of effect include improved ventricular relaxation, and increased diastolic filling time but its impact on HCM pathophysiology remains unclear. The results of genetic and pharmacological studies in animal models suggest that cardiac hypertrophy and fibrosis in HCM are potentially reversible. However, current pharmacological treatments of HCM in patients, while are effective for symptomatic improvement, have not been established to prevent, ameliorate, or reverse cardiac hypertrophy in patients. An effective treatment of HCM has to target the molecular mechanisms that are involved in the pathogenesis of the phenotype and novel pharmacological therapies are moving in that direction. In this review, we analyse potential beneficial effects of specific experimental pharmacological agents on decreasing myocardial hypertrophy, regression of fibrosis or improving myocardial metabolic efficiency.
Keywords: Hypertrophic cardiomyopathy, fibrosis, losartan, spironolactone, statins, calcineurin inhibitors, perhexiline, Nacetylcysteine, HCM, HMG-CoA, NF-AT3, CsA, TGF
Medicinal Chemistry
Title: An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
Volume: 7 Issue: 4
Author(s): Esteban Orenes-Pinero, Diana Hernandez-Romero, Eva Jover, Gonzalo de la Morena, Mariano Valdes and Francisco Marin
Affiliation:
Keywords: Hypertrophic cardiomyopathy, fibrosis, losartan, spironolactone, statins, calcineurin inhibitors, perhexiline, Nacetylcysteine, HCM, HMG-CoA, NF-AT3, CsA, TGF
Abstract: Hypertrophic cardiomyopathy (HCM) is microscopically characterized by cardiomyocyte hypertrophy, myofibrillar disarray, and fibrosis. During the evolvement of the hypertrophic disease, myocardium suffers a heterogeneous remodeling which includes enhancement of extracellular matrix. The most commonly used pharmacological agents are β- blockers and verapamil, a calcium antagonist, which are the mainstay of therapy. Their proposed mechanisms of effect include improved ventricular relaxation, and increased diastolic filling time but its impact on HCM pathophysiology remains unclear. The results of genetic and pharmacological studies in animal models suggest that cardiac hypertrophy and fibrosis in HCM are potentially reversible. However, current pharmacological treatments of HCM in patients, while are effective for symptomatic improvement, have not been established to prevent, ameliorate, or reverse cardiac hypertrophy in patients. An effective treatment of HCM has to target the molecular mechanisms that are involved in the pathogenesis of the phenotype and novel pharmacological therapies are moving in that direction. In this review, we analyse potential beneficial effects of specific experimental pharmacological agents on decreasing myocardial hypertrophy, regression of fibrosis or improving myocardial metabolic efficiency.
Export Options
About this article
Cite this article as:
Orenes-Pinero Esteban, Hernandez-Romero Diana, Jover Eva, de la Morena Gonzalo, Valdes Mariano and Marin Francisco, An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy, Medicinal Chemistry 2011; 7 (4) . https://dx.doi.org/10.2174/157340611796150941
DOI https://dx.doi.org/10.2174/157340611796150941 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure
Current Pharmaceutical Design The Effects of Vitamin C on Adriamycin-Induced Hypercholesterolemia in Rat
Current Nutrition & Food Science Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Regulation of Intracellular Cardiomyocyte Calcium Stores by Peptides: A New Approach to Cardiac Protection
Current Medicinal Chemistry Chromatin Remodeling, DNA Damage Repair and Aging
Current Genomics 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry The Cardiac Conduction and Contractility Complications of Methamphetamine Use and the Relationship to Psychiatric Comorbidity: A Systematic Review
Current Psychiatry Research and Reviews Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews Targeting Resveratrol to Mitochondria for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Uncontrolled Hypertension and Oncology: Clinical Tips
Current Vascular Pharmacology The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Thyroid Disorders in Chronic Heart Failure: From Prognostic Set-up to Therapeutic Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetic Cardiomyopathy: Electromechanical Cellular Alterations
Current Vascular Pharmacology Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Natural Products to Anti-trypanosomal Drugs: An Overview of New Drug Prototypes for American Trypanosomiasis
Cardiovascular & Hematological Agents in Medicinal Chemistry Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Pharmacokinetics of Antifungal Agents in Neonates and Young Infants
Current Medicinal Chemistry Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design